Microfluidic Device by Tai, Yu-Chong et al.
1111111111111111111immu1111111111u~
(12) United States Patent
Tai et al.
(54) MICROFLUIDIC DEVICE
(71) Applicant: California Institute of Technology,
Pasadena, CA (US)
(72) Inventors: Yu-Chong Tai, Pasadena, CA (US);
Siyang Zheng, Pasadena, CA (US);
Jeffrey Chun-Hui Lin, Pasadena, CA
(US); Harvey L. Kasdan, Chatsworth,
CA (US)
(73) Assignee: California Institute of Technology,
Pasadena, CA (US)
(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.
(21) Appl. No.: 15/355,696
(22) Filed: Nov. 18, 2016
(65) Prior Publication Data
US 2017/0136463 Al May 18, 2017
Related U.S. Application Data
(60) Continuation of application No. 14/931,645, filed on
Nov. 3, 2015, now Pat. No. 9,535,059, which is a
(Continued)
(51) Int. Cl.
GOIN 33/50 (2006.01)
GOIN 33/58 (2006.01)
(Continued)
(52) U.S. Cl.
CPC ... BOIL 3/502761 (2013.01); BOIL 3/502753
(2013.01); BOIL 220010636 (2013.01);
(Continued)
(58) Field of Classification Search
CPC ..... BOIL 2200/0636; BOIL 2200/0647; BOIL
(io) Patent No.: US 9,757,729 B2
(45) Date of Patent: Sep. 12, 2017
2300/0681; BOIL 2300/0816; BOIL
2300/0822; BOIL 2300/0864; BOIL
2300/0877; BOIL 3/502753; BOIL
3/502761; BOIL 2400/086;
(Continued)
(56) References Cited
U.S. PATENT DOCUMENTS
4,233,029 A 11/1980 Columbus
4,376,820 A 3/1983 Giannini et al.
(Continued)
FOREIGN PATENT DOCUMENTS
CN 10108261 B 12/2012
CN ZL 200880015296.7 4/2014
(Continued)
OTHER PUBLICATIONS
U.S. Appl. No. 60/922,296, filed Apr. 6, 2007, Tai et al.
(Continued)
Primary Examiner Maureen Wallenhorst
(74) Attorney, Agent, or Firm Hema Vakharia-Rao;
Nixon Peabody LLP
(57) ABSTRACT
Described herein are particular embodiments relating to a
microfluidic device that may be utilized for cell sensing,
counting, and/or sorting. Particular aspects relate to a micro-
fabricated device that is capable of differentiating single cell
types from dense cell populations. One particular embodi-
ment relates a device and methods of using the same for
sensing, counting, and/or sorting leukocytes from whole,
undiluted blood samples.
20 Claims, 10 Drawing Sheets
https://ntrs.nasa.gov/search.jsp?R=20170009512 2019-08-31T01:58:25+00:00Z
US 9,757,729 B2
Page 2
Related U.S. Application Data
continuation of application No. 14/685,480, filed on
Apr. 13, 2015, now Pat. No. 9,234,884, which is a
continuation of application No. 14/296,199, filed on
Jun. 4, 2014, now Pat. No. 9,029,158, which is a
division of application No. 12/062,808, filed on Apr.
4, 2008, now abandoned.
(60) Provisional application No. 60/922,296, filed on Apr.
6, 2007.
(51) Int. Cl.
GOIN 15/06 (2006.01)
GOIN 15/10 (2006.01)
GOIN 15/14 (2006.01)
BOIL 3/00 (2006.01)
(52) U.S. Cl.
CPC .................. BOIL 220010647 (2013.01); BOIL
230010636 (2013.01); BOIL 230010654
(2013.01); BOIL 230010681 (2013.01); BOIL
230010816 (2013.01); BOIL 230010822
(2013.01); BOIL 230010864 (2013.01); BOIL
230010877 (2013.01); BOIL 24001086
(2013.01); COIN 3315005 (2013.01); COIN
3315094 (2013.01); COIN 331582 (2013.01)
(58) Field of Classification Search
CPC ........... GOIN 15/1056; GOIN 15/1484; GOIN
2015/1006; GOIN 2015/1486; GOIN
2015/149; GOIN 33/5005; GOIN
33/5094; GOIN 33/582; YIOT 436/11;
YIOT 436/13; YIOT 436/25; YIOT
436/2575
USPC ....... 436/10, 43, 56, 63, 164, 172, 174, 180;
422/68.1, 73, 82.05, 82.08, 501, 502, 503,
422/505; 435/29
See application file for complete search history.
(56) References Cited
U.S. PATENT DOCUMENTS
4,400,370 A 8/1983 Kass
4,730,899 A 3/1988 Kime et al.
4,745,285 A 5/1988 Recktenwald et al.
4,882,284 A 11/1989 Kirchanski et al.
5,126,276 A 6/1992 Fish et al.
5,304,487 A 4/1994 Wilding et al.
5,311,426 A 5/1994 Donohue et al.
5,716,852 A 2/1998 Yager et al.
5,837,115 A 11/1998 Austin et al.
5,932,100 A 8/1999 Yager et al.
5,972,710 A 10/1999 Weigl et al.
6,136,610 A 10/2000 Polito et al.
6,168,948 B1 1/2001 Anderson et al.
6,372,516 B1 4/2002 Sun
6,426,230 B1 7/2002 Feistel
6,551,841 B1 4/2003 Wilding et al.
6,635,163 B1 10/2003 Han et al.
6,637,463 B1 10/2003 Lei et al.
6,674,525 B2 1/2004 Bardell et al.
6,852,284 B1 2/2005 Holl et al.
6,897,954 B2 5/2005 Bishop
7,105,355 B2 9/2006 Kurabayashi et al.
7,192,560 B2 3/2007 Parthasarathy et al.
7,247,274 B1 7/2007 Chow
7,347,976 B2 3/2008 Parthasarathy et al.
7,553,453 B2 6/2009 Gu et al.
7,718,421 B2 5/2010 Chen et al.
8,116,984 B2 2/2012 Davis et al.
D669,191 S 10/2012 Handique
8,318,109 B2 11/2012 Saltsman et al.
8,364,418 B2 1/2013 Davis et al.
8,518,705 B2 8/2013 Chan et al.
9,029,158 B2 5/2015 Tai et al.
9,234,884 B2 1/2016 Tai et al.
9,535,059 B2 1/2017 Tai et al.
2001/0008760 Al 7/2001 King et al.
2002/0031255 Al 3/2002 Kasdan et al.
2002/0177174 Al 11/2002 Zock et al.
2003/0002037 Al 1/2003 Kasdan et al.
2003/0073089 Al 4/2003 Mauze et al.
2003/0170881 Al 9/2003 Davis et al.
2003/0175990 Al 9/2003 Hayenga et al.
2003/0233827 Al 12/2003 Kuo et al.
2004/0126008 Al 7/2004 Chapoulaud et al.
2004/0155309 Al 8/2004 Sorm
2005/0105077 Al 5/2005 Padmanabhan et al.
2005/0148093 Al 7/2005 Chien
2005/0221281 Al 10/2005 Ho
2005/0255600 Al 11/2005 Padmanabhan et al.
2005/0261560 Al 11/2005 Ridder et al.
2005/0275839 Al 12/2005 Robinson et al.
2006/0011862 Al 1/2006 Bernstein
2006/0134712 Al 6/2006 Stromgren et al.
2007/0227890 Al 10/2007 Ramsey et al.
2007/0253868 Al 11/2007 Beebe et al.
2007/0292941 Al 12/2007 Handique et al.
2008/0101993 Al 5/2008 Andersson et al.
2008/0212102 Al 9/2008 Nuzzo et al.
2009/0042241 Al 2/2009 Yu-Chong et al.
2009/0117605 Al 5/2009 Davis et al.
2010/0051124 Al 3/2010 Imran
2010/0093019 Al 4/2010 Ditcham et al.
2011/0184537 Al 7/2011 Kasdan et al.
2012/0071342 Al 3/2012 Lochhead et al.
2012/0177543 Al 7/2012 Battrell et al.
2012/0266986 Al 10/2012 Wimberger-Friedl et al.
2012/0275972 Al 11/2012 Schoen et al.
2013/0102087 Al 4/2013 Kasdan et al.
2013/0137135 Al 5/2013 Tai et al.
2013/0230867 Al 9/2013 Davis et al.
20 14/03 77 742 Al 12/2014 Tai et al.
2015/0309011 Al 10/2015 Tai et al.
FOREIGN PATENT DOCUMENTS
WO WO 01/68238 A2 9/2001
WO WO 2006/055816 A2 5/2006
WO WO 2006/118586 A2 11/2006
WO WO 2008/121828 A2 10/2008
WO WO 2008/124589 A2 10/2008
WO WO 2009/144660 Al 12/2009
WO WO 2011/094577 A2 8/2011
WO WO 2011/128893 A3 3/2012
WO WO 2012/092010 Al 7/2012
WO WO 2014/097286 Al 6/2014
WO WO 2014/097287 Al 6/2014
OTHER PUBLICATIONS
Adams, et al. Fluorometric characterization of six classes of human
leukocytes. Acta Cytol. Sep.-Oct. 1974; 18(5): 389-391.
Adams, et al. Machine characterization of human leukocytes by
acridine orange fluorescence. Acta Cytol. May-Jun. 1971; 15(3):
289-291.
Altendorf, et al. Differential Blood Cell Counts Obtained Using a
Microchannel Based Flow Cytometer. Transducers. 1997 Jun.
16-19, 1997; 1: 531-534.
Assicot, et al. High serum procalcitonin concentrations in patients
with sepsis and infection. Lancet. Feb. 27, 1993; 341(8844): 515-
518.
Aulesa, et al. Validation of the Coulter LH 750 in a hospital
reference laboratory. Lab Hematol. 2003; 9(1): 15-28.
Ault, Kenneth A. Flow cytometric measurement of platelet function
and reticulated platelets. Annals of the New York Academy of
Sciences. Mar. 20, 1993; 677: 293-308.
Bhattacharya, et al. Studies on Surface Wettability of
Poly(Dimethyl) Siloxane (PDMS) and Glass Under Oxygen-Plasma
US 9,757,729 B2
Page 3
(56) References Cited
OTHER PUBLICATIONS
Treatment and Correlation With Bond Strength. J.
Microelectromechan. Syst. Jun. 2005; 14: 590-597.
Bj ornsson, et al., Total Nucleated cell differential for blood and bone
marrow using a single tube in a five-color flow cytometer.
Cytometry Part B clinical cytometry. Mar. 2008. 7413:91-103.
Blajchman, et al. Bacterial detection of platelets: current problems
and possible resolutions. Transfusion medicine reviews. Oct.
2005;19(4):259-272.
Bodensteiner, David C. A flow cytometric technique to accurately
measure post-filtration white blood cell counts. Transfusion. Sep.
1989; 29(7): 651-653.
Cheson, et al. National Cancer Institute-sponsored Working Group
guidelines for chronic lymphocytic leukemia: revised guidelines for
diagnosis and treatment. Blood. 1996; 87(12): 4990-4997.
Christ-Crain, et al. Effect of procalcitonin-guided treatment on
antibiotic use and outcome in lower respiratory tract infections:
cluster-randomised, single-blinded intervention trial. Lancet. Feb.
21, 2004; 363(9409): 600-607.
Cristofanilli, et al. Circulating tumor cells, disease progression, and
survival in metastatic breast cancer. N Engl J Med. Aug. 19, 2004;
351(8): 781-791.
Davis, et al. Neutrophil CD64 is an improved indicator of infection
or sepsis in emergency department patients. Arch Pathol Lab Med.
May 2006; 130(5): 654-661.
Dieye, et al. Absolute CD4 T-cell counting in resource-poor set-
tings: direct volumetric measurements versus bead-based clinical
flow cytometry instruments. J Acquit Immune Defic Syndr. May 1,
2004; 39(1): 32-37.
Divers, et al. Quantitation of CD62, soluble CD62, and lysosome-
associated membrane proteins 1 and 2 for evaluation of the quality
of stored platelet concentrates. Transfusion. Apr. 1995; 35(4):
292-297.
Drexler, et al. Diagnostic value of immunological leukemia
phenotyping. Acta Haematol. 1986; 76(1): 1-8.
Dziegiel, et al. Detecting fetomaternal hemorrhage by flow
cytometry. Cliff Opin Hematol. Nov. 2006; 13(6): 490-495.
Fischer, et al. Reducing costs in flow cytometric counting of
residual white blood cells in blood products: utilization of a single
platform bead free flow rate calibration method. Transfusion. Jul.
2011; 51(7): 1431-1438.
Fujimoto, Keiji. Principles of Measurement in Hematology Ana-
lyzers Manufactured by Sysmex Corporation. Sysmex Journal Inter-
national. 1999; 9(1): 31-44.
Gawad, et al. Micromachined impedance spectroscopy flow
cytometer for cell analysis and particle sizing. Lab Chip. Sep. 2001;
1(1): 76-82.
Graff, et al. Close relationship between the platelet activation
marker CD62 and the granular release of platelet-derived growth
factor. J Pharmacol Exp Ther. Mar. 2002; 300(3): 952-957.
Groselj-Gren, et al. Neutrophil and monocyte CD64 and CD163
expression in critically ill neonates and children with sepsis: com-
parison of fluorescence intensities and calculated indexes. Media-
tors Inflamm. 2008;2008:202646. doi: 10.1155/2008/202646.
Guerti, et al. Performance evaluation of the PENTRA 60C+ auto-
mated hematology analyzer and comparison with the ADVIA 2120.
Int J Lab Hematol. Apr. 2009; 31(2): 132-141.
Hawkins, Robert C. Laboratory turnaround time. The Clinical
Biochemist Reviews. Nov. 2007; 28(4): 179-194.
Hershman, et al. Monocyte HLA-DR antigen expression character-
izes clinical outcome in the trauma patient. Br. J. Surg. Feb. 1990;
77(2): 204-207.
Hilfrich, et al. Prognostic relevance of human papillomavirus L1
capsid protein detection within mild and moderate dysplastic lesions
of the cervix uteri in combination with p16 biomarker. Anal Quant
Cytol Histol. Apr. 2008; 30(2): 78-82.
Hillier, et al. A case-control study of chorioamnionic infection and
histologic chorioamnionitis in prematurity. N. Engl. J. Med. Oct. 13,
1988; 319(15): 972-978.
Hoffmann, Johannes JML. Neutrophil CD64 as a sepsis biomarker.
Biochem Med (Zagreb). 2011; 21(3): 282-290.
Holmes, et al. High throughput particle analysis: combining
dielectrophoretic particle focussing with confocal optical detection.
Biosens Bioelectron. Feb. 15, 2006; 21(8): 1621-1630.
Hughes-Jones, et al. Differential white cell counts by frequency
distribution analysis of cell volumes. J. Clin. Pathol. Aug. 1974;
27(8): 623-625.
IPRP and WO in PCT/US2008/059408, dated Oct. 6, 2009.
ISR in PCT/US2008/059408, dated Oct. 17, 2008.
Jackson, JF. Supravital blood studies, using acridine orange fluo-
rescence. Blood. May 1961; 17: 643-649.
Kass, L. Identification of lymphocyte subpopulations with a
polymethine dye. J. Histochem. Cytochem. Jul. 1988; 36(7): 711-
715.
Kass, L. Staining of granulocytic cells by Chlorazol black E. Am J.
Clin. Pathol. Dec. 1981; 76(6): 810-812.
Kibe, et al. Diagnostic and prognostic biomarkers of sepsis in
critical care. J Antimicrob Chemother. Apr. 2011; 66 Suppl 2:
ii33-40.
Larosa, et al. Biomarkers: the future. Crit. Care Clin. Apr. 2011;
27(2): 407-419.
Lee, et al. A flow-rate independent counter using a fixed control
volume between double electrical sensing zones. Proceedings of the
18th IEEE International Conference on Micro Electro Mechanical
Systems (MEMS). 2005. 678-681.
Lee, et al. Micromachine-based multi-channel flow cytometers for
cell/particle counting and sorting. J. Micromechanics and
Microengineering. 2005; 15(3): 447-454.
Liu, et al. Improved quantitative Apt test for detecting fetal hemo-
globin in bloody stools of newborns. Clin. Chem. Nov. 1993; 39(11
Pt 1): 2326-2329.
Loran, et al. Bladder cancer screening in a high risk asymptomatic
population using a point of care urine based protein tumor marker.
J Urol. Jul. 2009; 182(1): 52-57.
Masse, et al. Validation of a simple method to count very low white
cell concentrations in filtered red cells or platelets. Transfusion.
Jul.-Aug. 1992; 32(6): 565-571.
Matic, et al. Whole blood analysis of reticulated platelets: improve-
ments of detection and assay stability. Cytometry. Oct. 15, 1998;
34(5): 229-234.
McDonald, et al. Use of a solid-phase fluorescent cytometric
technique for the detection of bacteria in platelet concentrates.
Transfus Med. Jun. 2005; 15(3): 175-183.
Michelson, Alan D. Flow cytometry: a clinical test of platelet
function. Blood. Jun. 15, 1996; 87(12): 4925-4936.
Miller, et al. Proteomics in Microfluidic Devices. In Encyclopedia
of Micro- and Nanofluidics; Li, D. Q., Ed.; Springer: Heidelberg,
Germany, 2008; 3: 1749-1758.
Morgan, et al. High speed simultaneous single particle impedance
and fluorescence analysis on a chip. Curr. Appl. Phys. 2006; 6:
367-370.
Moriyama, et al. Acridine Orange as a Fluorescent Probe for
Lysosomal Proton Pump3. J. Biochem. 1982; 92: 1333-1336.
Moro, et al. A new broad-spectrum cancer marker. Vitro Diagnostic
Technology. Jun. 1, 2005; 1-3.
Niehren, et al. An All-Solid-State Flow Cytometer for Counting
Fluorescent Microspheres. Anal. Chem. 1995; 67(15): 2666-2671.
Oberjat, et al. Rapid and reliable differential counts on dilute
leukocyte suspensions. J. Lab. Clin. Med. Sep. 1970; 76(3): 518-
522.
Perry, et al. Is low monocyte HLA-DR expression helpful to predict
outcome in severe sepsis? Intensive Care Med. Aug.
2003;29(8):1245-1252.
Ramakumar, et al. Comparison of screening methods in the detec-
tion of bladder cancer. J Urol. Feb. 1999; 161(2): 388-394.
Rawstron, et al. Quantitation of minimal disease levels in chronic
lymphocytic leukemia using a sensitive flow cytometric assay
improves the prediction of outcome and can be used to optimize
therapy. Blood. Jul. 1, 2001; 98(1): 29-35.
Rodriguez, et al. A microchip CD4 counting method for HIV
monitoring in resource-poor settings. PLoS Med. Jul. 2005; 2(7):
e182.
US 9,757,729 B2
Page 4
(56) References Cited
OTHER PUBLICATIONS
Rylatt, et al. An immunoassay for human D dimer using monoclonal
antibodies. Thromb Res. Sep. 15, 1983; 31(6): 767-778.
Sacks, et al. Guidelines and recommendations for laboratory analy-
sis in the diagnosis and management of diabetes mellitus. Clin
Chem. Mar. 2002; 48(3): 436-472.
Satake, et al. A sensor for blood cell counter using MEMS tech-
nology. Sensors and Actuators B: Chemical. 2002; 83(1): 77-81.
Segal, et al. Accuracy of platelet counting haematology analysers in
severe thrombocytopenia and potential impact on platelet transfu-
sion. Br. J. Haematol. Feb. 2005; 128(4): 520-525.
Shapiro, et al. Combined blood cell counting and classification with
fluorochrome stains and flow instrumentation. J Histochem
Cytochem. Jan. 1976; 24(1): 396-411.
Shapiro, et al. Cytomat-R: a computer-controlled multiple laser
source multiparameter flow cytophotometer system. J Histochem
Cytochem. Jul. 1977; 25(7): 836-844.
Sheehan, et al. An improved method of staining leucocyte granules
with Sudan black B. J Pathol Bacteriol. Jan.-Apr. 1947; 59(1-2):
336-337.
Simonnet, et al. High-throughput and high-resolution flow
cytometry in molded microfluidic devices. Anal Chem. Aug. 15,
2006; 78(16): 5653-5663.
Stein, et al. D-dimer for the exclusion of acute venous thrombosis
and pulmonary embolism: a systematic review. Ann Intern Med.
Apr. 20, 2004; 140(8): 589-602.
Steinkamp, et al. Multiparameter Cell Sorting: Identification of
Human Leukocytes by Acridine Orange Fluorescence. Acta Cytol.
1973; 17: 113-117.
Sutherland, et al. The ISHAGE guidelines for CD34+ cell determi-
nation by flow cytometry. J Hematother. Jun. 1996; 5(3): 213-226.
Tatsumi, et al. Principle of blood cell counter—development of
electric impedance method. Sysmex J. Int. 1999; 9(1): 8-20.
Tibbe, et al. Optical tracking and detection of immunomagnetically
selected and aligned cells. Nat Biotechnol. Dec. 1999; 17(12):
1210-1213.
Van Dilla, et al. Volume distribution and separation of normal
human leucocytes. Proc. Soc. Exp. Bio. Med. Jun. 1967;
125(2):367-370.
Wang, et al. "Reticulated platelets predict platelet count recovery
following chemotherapy." Transfusion. Mar. 2002; 42(3): 368-374.
Weigl, et al. Design and rapid prototyping of thin-flim laminate-
based microfluidic devices. Biomed Microdev. 2001; 3: 267-274.
Yang, et al. A cell counting/sorting system incorporated with a
microfabricated flow cytometer chip. Meas. Sci. Technol. 2006; 17:
2001-2009.
Notice of allowance dated Jan. 23, 2015 for U.S. Appl. No.
14/296,199.
Notice of allowance dated Aug. 14, 2015 for U.S. Appl. No.
14/685,480.
Notice of allowance dated Aug. 21, 2014 for U.S. Appl. No.
14/296,317.
Office action dated Apr. 6, 2012 for U.S. Appl. No. 12/062,808.
Office action dated Apr. 14, 2011 for U.S. Appl. No. 12/062,808.
Office action dated Jun. 25, 2010 for U.S. Appl. No. 12/062,808.
Office action dated Jul. 12, 2013 for U.S. Appl. No. 12/062,808.
Office action dated Sep. 17, 2010 for U.S. Appl. No. 12/062,808.
Office action dated Nov. 5, 2012 for U.S. Appl. No. 12/062,808.
Office action dated Dec. 4, 2013 for U.S. Appl. No. 12/062,808.
Office action dated Dec. 9, 2010 for U.S. Appl. No. 12/062,808.
Office action dated Oct. 8, 2014 for U.S. Appl. No. 14/296,199.
OA in CN 200880015296.7, dated Sep. 20, 2012.
OA in CN 200880015296.7, dated Oct. 18, 2011.
EP Application No. 08733132.8 Examination Report dated Dec. 9,
2016; 5 pages.
U.S. Appl. No. 14/931,645 Notice of Allowance dated Nov. 25,
2016; 6 pages.
U.S. Patent Sep. 12, 2017 Sheet 1 of 10
FIG. lA
FIG. 1B
:•
200
270
260
FIG.1
230
210
r
220
FIG.2
US 9,757,729 B2
290
240
250
U.S. Patent Sep.12, 2017 Sheet 2 of 10 US 9,757,729 B2
U.S. Patent Sep.12, 2017 Sheet 3 of 10 US 9,757,729 B2
IGAD
0.9
Si~sE
.
NTEN'STY
0,8
B 
l G . ` fl..!
T'W;Y (SEC(I"J ?)
'G.
FIG, 41i"
91
U.R. Patent Se .l2 2017 Sheet 4 of 10 US 9,737 729 G2
{}G.GA.
Fib.H
0,74
1&73
d72
0.70
V0 y\E 0 J
(VOLT) 0 $ 8
d 67
d 66
G±5
0,64
2ME (3 ON
'FlƒG,?
{ƒG ,6C
U.S. Patent Sep. 12, 2017 Sheet 5 of 10 US 9,757,729 B2
IGM
U.S. Patent Sep.12, 2017 Sheet 6 of 10 US 9,757,729 B2
:a..3
S
7~'
U.S. Patent Sep.12, 2017 Sheet 7 of 10 US 9,757,729 B2
r
f, 0) ! r~.~..
CCELL
E,lEv,..
R
y
~y
S.~
1j" JO
U.S. Patent Sep.12, 2017 Sheet 8 of 10 US 9,757,729 B2
F I J 2
U.S. Patent Sep.12, 2017 Sheet 9 of 10 US 9,757,729 B2
ZU
FIG . 12B
U.R. Patent Se .l2 2017 Sheet 10 of 10 US 9,737 729 G2
!ƒG 
5 
> 1 
A.g.
! 9 A i
1I G .ƒ3 5
US 9,757,729 B2
MICROFLUIDIC DEVICE
CROSS-REFERENCE TO RELATED
APPLICATIONS
This application claims the benefit of priority under 35
U.S.C. §120 as a continuation of U.S. patent application Ser.
No. 14/931,645, filed Nov. 3, 2015, and issued as U.S. Pat.
No. 9,535,059 on Jan. 3, 2017, which is a continuation of
U.S. patent application Ser. No. 14/685,480, filed Apr. 13,
2015, and issued as U.S. Pat. No. 9,234,884 on Jan. 12,
2016, which is a continuation of U.S. patent application Ser.
No. 14/296,199, filed Jun. 4, 2014, and issued as U.S. Pat.
No. 9,029,158 on May 12, 2015, which is a divisional of
U.S. patent application Ser. No. 12/062,808, filed Apr. 4,
2008, now abandoned, which claims priority under 35
U.S.C. §119(e) to U.S. provisional patent application No.
60/922,296, filed Apr. 6, 2007, now expired, the contents of
each of which are herein incorporated by reference in their
entirety.
STATEMENT OF GOVERNMENT INTEREST
This work was supported in part by the National Space
Biomedical Research Institute through NASA, grant number
NCC 9-58-317. The United States government has certain
rights in this invention.
FIELD OF THE INVENTION
The present disclosure relates to fabricated microfluidic
devices that can be utilized as cell sensors and/or actuators.
In certain embodiments, the microfluidic device may be
used for labeling, sensing, differentiating, and/or sorting
targets, particularly cell populations.
BACKGROUND OF THE INVENTION
Standard cell sensors or actuators are generally based on
flow cytometry and employ one or a combination of elec-
trical impedance sensing, light scattering measurement, and
chemical or immunostaining followed by optical sensing.
For differentiation of blood cells by electrical impedance
sensing, red blood cells are removed by lysing in order to
reduce the blood volume. Lysing is generally done through
the use of saponin or surfactants. During the lysing process,
the leukocyte cell volume changes depending on cell type,
due to the leakage of cytoplasm contents and cell nucleus
shrinkage in varying amounts. Fujimoto, Sysmex J. Int. 9
(1999). Thus, normally 2-part (lymphocytes versus granu-
locytes) or even 3-part (lymphocytes, neutrophils, and other
leukocytes) differential can be achieved by simple electrical
impedance measurement of particle volume. Hughes-Jones,
et al., J. Clin. Pathol. 27; 623-625 (1974); Oberjat, et al., J.
Lab. Clin. Med. 76; 518 (1970); Vandilla, et al., Proc. Soc.
Exp. Biol. Med. 125; 367 (1967); Maeda, et al., Clin. Pathol.
27; 1117-1200 (1979); Maeda, et al., Clin. Pathol. 9; 555-
558 (1982). Combining direct current and alternating current
impedance, special acidic hemolysis in basophile channel
and alkali hemolysis in eosinophil channel, a 5-part leuko-
cyte differential can be achieved. Tatsumi, et al., Sysmex J.
Int. 9; 9-20 (1999).
Alternative optical methods are based on light scattering
and fluorescence staining of organelles, granules, and nuclei.
Generally, low-angle scattered light contains information on
cell size and high-angle scattered light can be used to probe
internal composition of the cell. To achieve 5-part differen-
2
tial, certain leukocyte populations, such as eosinophils,
require special stain to change its scattering characteristics
from other granulocytes, and basophils typically need to be
counted separately following the differential lysis of other
5 leukocytes. McKenzie, Clinical Laboratory Hematology,
Prentice Hall, 2004; Fujimoto, Sysmex J. Int. 9 (1999).
In general, conventional automated cell analyzers are
bulky, expensive, and mechanically complex, which restricts
their locations to hospitals or central laboratories. Conven-
10 tional cell analyzers require larger sample volumes and
generate more waste than the systems developed using
microdevices. Furthermore, for analysis of certain cell types,
such as leukocytes, accuracy and speed of counting, differ-
15 entiation, and/or sorting is important for determining disease
state and treatment.
BRIEF DESCRIPTION OF THE SEVERAL
VIEWS OF THE DRAWING(S)
20
FIG. 1A shows the molecular structure of acridine orange.
FIG. 1B shows leukocyte staining results with acridine
orange.
FIG. 2 shows the top view of one embodiment of a novel
25 fabricated microfluidic apparatus.
FIG. 3 shows one embodiment of the optical system
setup.
FIG. 4A shows erythrocyte concentration in whole blood.
FIG. 4B shows leukocyte staining in whole blood with
30 acridine orange at a concentration of 100 ng/mL.
FIG. 4C shows leukocyte staining in whole blood with
acridine orange at a concentration of 1µg/mL.
FIG. 4D shows leukocyte staining in whole blood with
35 acridine orange at a concentration of 10 µg/mL.
FIG. 4E shows leukocyte staining in whole blood with
acridine orange at a concentration of 100 µg/mL.
FIG. 4F shows leukocyte staining in whole blood with
acridine orange at a concentration of 1 mg/mL.
40 FIG. 5 shows fluorescent signal bleaching from a single
leukocyte in one embodiment.
FIG. 6A shows an image of background and a 5µm bead
with focused laser illumination flow taken by CCD camera
with long pass emission filter, according to one embodiment.
45 FIG. 6B shows an image of background and a 5µm bead
with laser illumination flow taken by CCD camera with long
pass emission filter, according to one embodiment.
FIG. 6C shows an image of background and a 5µm bead
with diffused laser illumination flow taken by CCD camera
50 with long pass emission filter, according to one embodiment.
FIG. 6D shows an image of background and the trace of
a 5µm bead with diffused laser illumination flow taken by
CCD camera with long pass emission filter, according to one
embodiment.
55 FIG. 7 shows a graph of detection of 5µm fluorescent
beads detection with photodiode detector with long pass
emission filter.
FIG. 8A shows background image of focused laser beam
from video taken by CCD camera with long pass emission
60 filter, according to one embodiment.
FIG. 88 shows a signal from a leukocyte from diluted
whole blood testing from video taken by CCD camera with
long pass emission filter, according to one embodiment.
FIG. 9 shows the time trace of amplified photodiode
65 signal of acridine orange stained undiluted whole blood with
green emission filter centered at 525 mu, and peaks labeled,
according to one embodiment.
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FIG. 10 shows a histogram of signal intensity from
photodiode detector with green emission filter centered at
525 mu.
FIG. 11 shows a histogram of signal intensity from
photodiode detector with red emission filter centered at 650
run.
FIG. 12A shows an illustration of a handheld detection
box instrument according to one embodiment.
FIG. 12B shows an assembled detection box instrument
according to one embodiment.
FIG. 13A shows the top view of an apparatus according
to one particular embodiment.
FIG. 13B shows the top view of an apparatus according
to one particular embodiment.
SUMMARY OF THE INVENTION
Certain embodiments disclosed herein include a micro-
fluidic apparatus comprising a substrate having a first chan-
nel having a defined physical feature, wherein said first
channel is in fluid communication with at least one inlet for
receiving a fluid, wherein said first channel leads to a
restrictive access, and wherein said first channel is in fluid
communication with a second channel having a defined
physical feature, wherein said second channel is in fluid
communication with at least one fluid flow outlet; and a fluid
biological sample. In certain embodiments, said defined
physical feature is a depression or protrusion. In particular
embodiments, said fluid biological sample comprises blood.
In certain embodiments, the microfluidic apparatus further
comprises a detection zone, and/or a filter array, each in fluid
communication with said channel and said fluid flow outlet.
Amicrofluidic apparatus comprising a substrate having at
least one first channel having a defined physical feature; at
least one first inlet formed in said first channel for receiving
a first fluid; wherein said first channel is in fluid communi-
cation with a bifurcated channel, wherein said bifurcated
channel is in fluid communication with a third channel
detection zone; at least one second inlet for receiving a
second fluid, wherein said second inlet is in fluid commu-
nication with a branched channel; a filter structure in fluid
communication with a reservoir, wherein said reservoir is in
fluid communication with said third channel detection zone;
at least one fluid flow outlet formed in said third channel;
and a fluid sample; wherein the ratio of the cross-sectional
area of said second channel compared to the cross-sectional
area of said first channel is 1:10. In certain embodiments, the
defined physical feature is a depression or a protrusion.
In certain embodiments, said filter structure comprises a
filter array, said first fluid comprises sheath fluid and said
second fluid comprises blood.
Certain embodiments disclosed herein relate to a detec-
tion system comprising a microfluidic apparatus and further
comprising a light source; a lens assembly; a filter assembly;
and an image capture device. In some embodiments, the
detection system further comprises at least one display unit
or at least one recording unit. In certain particular embodi-
ments, said excitation source comprises a laser, particularly
an argon laser. In particular embodiments, said filter assem-
bly comprises an excitation filter, and at least one emission
filter. In certain embodiments, said filter assembly further
comprises at least one aperture and at least one neutral
density filter. In particular embodiments, said filter assembly
further comprises at least one glass polarizer.
In certain embodiments, the lens assembly of the detec-
tion system comprises at least one condenser lens, at least
one objective lens, and at least one beamsplitter. In particu-
4
lar embodiments, said image capture device comprises at
least one CCD camera, CMOS device, photodiode, or pho-
tomultiplier tube. In certain embodiments, said filter assem-
bly comprises at least two emission filters and said image
5 capture device comprises at least one photomultiplier tube.
In certain embodiments, said display unit comprises a com-
puter and said recording unit comprises an oscilloscope. In
particular embodiments, said excitation source comprises an
argon laser; said lens assembly comprises a condenser lens,
10 an objective lens, and a beamsplitter; said filter assembly
comprises an excitation filter, a pinhole aperture and a
neutral density filter, and at least one emission filter; said
image capture device comprises a CCD camera and a
photodiode, and said display unit comprises a personal
15 computer, and further comprising an amplifier.
In particular embodiments, said excitation source of the
detection system comprises an argon laser; said lens assem-
bly comprises a condenser lens, an objective lens, and a
beamsplitter, said filter assembly comprises an excitation
20 filter, at least one emission filter; said image capture device
comprises a photomultiplier tube, and said display unit
comprises a personal computer.
Other embodiments disclosed herein relate to a method
for identifying a target comprising providing a fluid sample
25 to at least one microfluidic apparatus, wherein said fluid
sample contains at least one dye; providing an excitation
source to induce at least one fluorescent signal in a target;
detecting the fluorescent signal using a sensor in the appa-
ratus; and identifying the target based in part on the analysis
30 of the fluorescent signal. In certain embodiments, said target
is selected from the group consisting of: cells, organelles,
nuclei, granules, DNA, and RNA. In other embodiments,
said target comprises a cell selected from the group consist-
ing of a monocyte, a granulocyte, a macrophage, a neutro-
35 phil, an eosinophil, a basophil, or other leukocyte. In specific
embodiments, said target comprises a leukocyte and said dye
comprises acridine orange. Particular embodiments of the
method further comprising counting or sorting the target in
the sample by analysis of the fluorescent signal. In certain
40 embodiments, said fluid sample comprises blood.
DETAILED DESCRIPTION OF THE
INVENTION
45 The present disclosure relates to fabricated microfluidic
devices that can be utilized as cell sensors and/or actuators.
In certain embodiments, the microfluidic device may be
used for labeling, sensing, differentiating, and/or sorting cell
populations.
50 Microfluidic cell sensors and actuators can provide cell
sensing and counting for a more accurate outcome and a
lower cost. Particle counting (including bead, erythrocyte,
and cultured cell) has been demonstrated, for example, by
electrical impedance sensing, light scattering detection, and
55 fluorescent sensing. Gawad, et al. Lab Chip 1; 78 (2001);
Lee, et al. Proceedings of the 18th IEEE International
Conference on Micro Electro Mechanical Systems (MEMS)
678-681 (2005); Satake et al. Sens. Actuators B: Chem. 83;
77 (2002); Morgan, et al. Curr. Appl. Phys. 6, 367-370
60 (2006); Lee et al., J. Micromech. Microeng. 15; 447-454
(2005); Altendorf. et al. Proceedings of the International
Conference on Solid State Sensors and Actuators (Trans-
ducers '97) v. 1, p. 531, Chicago, Ill. (1997); Holmes et al.,
Biosens. Bloelectron. 21; 1621-1630 (2006); Yang et al.,
65 Meas. Sci. Technol. 17; 2001-2009 (2006); Simonnet et al.,
Anal. Chem, 78; 5653-5663 (2006); Niehren, et al., Anal.
Chem. 67; 2666-2671 (1995).
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In the area of optical sensing, microfabrication has
allowed development of microdevices to replace glass cap-
illary-based flow chambers, and to integrate compact optics
and provide on-chip sample transport.
Cell sensing and counting, particularly of leukocytes, is 5
cumbersome due in part to the cell population numbers. For
leukocyte differential in microdevices based on optical sens-
ing, a V-groove microchannel was fabricated by anisotropic
wet etching of a silicon substrate and 3-part leukocyte
differential was demonstrated for diluted blood without io
sheath flow by two-parameter light scattering. Altendorf,
Proceedings of the Int'l Conference on Solid State Sensors
and Actuators, v. 1, p. 531 (1997).
However, until the instant embodied disclosure, it was
necessary to dilute cell samples for cell sensors and actua- 15
tors for many reasons. One reason dilution has been neces-
sary is in order to prevent the coincidence effect in which
multiple cells appear in the detection zone simultaneously.
In human blood, the ratio of erythrocytes, or red blood cells,
to leukocytes is on the order of about a thousand to one, a 20
dilution factor of from about one hundred to several tens of
thousands is typically required to avoid erythrocyte inter-
ference for electrical impedance or light scattering detection.
Furthermore, for counting leukocytes in samples where
leukocytes are specifically fluorescently labeled, a dilution 25
of at least ten times is usually required. Sheenan and Storey,
J. Pathol. Bacteriol. 59; 336 (1947); Kass, J. Clin. Pathol.
76; 810-12 (1981); Weigl et al., Biomed. Microdeu 3;
267-274 (2001);
Dilution is also often required in order to avoid clogging 30
sample chambers, and also in order to remove erythrocytes
that are lysed prior to running the sample, particularly for
electrical impedance or light scattering detection. Some of
these protocols also require an additional fixation buffer.
Dyes 35
In the present disclosure, a dye, such as Acridine orange
(3,6-dimethylamineoacridine, FIG. 1), can be used to dif-
ferentiate a target, such as cells, organelles, granules, nuclei,
molecules (including double or single stranded nucleic
acids, such as DNA, or RNA, chromosomes, and also 40
including synthetic forms). In one particular embodiment,
leukocytes may be detected, counted, or sorted without need
for lysing erythrocytes or fixing the cell sample. Certain
dyes, such as Acridine orange, are also desirable due to the
fast diffusion into cells, easy commercial availability, and 45
excitation and emission wavelength compatibility with com-
mon light sources (i.e. argon laser and other broad spectrum
light sources in visible range) and optical filters. Kosenow,
Acta Haematol. 7, 217 (1952); Schiffer, Blood, 19, 200
(1962); Jackson, Blood, 17, 643 (1961); Hallermann et al., 50
Verh Deutsch Ges Inn Med. 70, 217 (1964).
Acridine orange is a pH-sensitive fluorescent cationic dye
that binds to double-stranded DNA by electrostatic attraction
and intercalation of the Acridine orange between base pairs.
Upon binding, the excitation maximum becomes 502 MU 55
and the emission maximum becomes 525 mn (green). Acri-
dine orange also binds to RNA and single-stranded DNA,
with a shifted excitation maximum of 460 mn and an
emission maximum of 650 nm (red). Adams and Kamentsky,
Acta Cytol. 15, 289 (1971); Adams and Kamentsky Acta 60
Cytol. 18, 389-91 (1974); Steinkam et al., Acta Cytol. 17,
113-17 (1973). Acridine orange is also desirable in that it is
hydrophobic in neutral pH, and can easily diffuse through
the cell membrane and cell nuclear membrane to bind to
RNA and DNA. In living cells. Acridine orange is proto- 65
nated in the acidic environment of lysosomes, which makes
it cationic and prevents the dye from leaking out of lysosome
T
membranes. Moriyama et al., J. Biochem. 92; 1333-36
(1982). When Acridine orange is used for leukocyte analy-
sis, the cell nucleus is stained green with slightly mixed red,
a result of double-stranded DNA and single-stranded RNA,
while the cell cytoplasm is stained red due to the RNA and
lysosomes. Thus, leukocyte counting can be achieved easily
by using the strong signal from the green fluorescent chan-
nel. Leukocyte differentiation can be achieved by analyzing
the signal from the red fluorescence channel.
For fresh-stained leukocytes, a 3-part differential (lym-
phocytes, monocytes, and granulocytes) can be achieved by
studying the red fluorescent signal of an Acridine orange
stained diluted blood sample, whereas a 5-part differential
leukocytes (lymphocytes, monocytes, neutrophils, eosino-
phils, and basophils) has been demonstrated with hypotonic
dilution and fresh Acridine orange-stained leukocyte
samples. Adams and Kamentsky, Acta Cytol. 15, 289 (1971);
Adams and Kamentsky, Acta Cytol. 18, 389-391 (1974);
Steinkam et al., Acta Cytol. 17, 113-17 (1973).
Other dyes can be utilized with certain embodiments
described in the instant disclosure, such as ethidium bro-
mide, three-dye combinations (ethidium bromide, brilliant
sulfaflavine, and stilbene disulfonic acid derivative);
oxazine dyes, basic orange 21, and a polymethine dye.
Shapiro, et al., J. Histochem. Cytochem. 24, 396-411 (1976);
Shapiro, et al., J. Histochem. Cytochem. 25, 836-844 (1977);
U.S. Pat. Nos. 4,376,820; 4,882,284; Tibbe, et al., Nat.
Biotechnol. 17, 1210-1213 (1999); U.S. Pat. No. 4,400,370;
Kass, J. Histochem. Cytochem. 36, 711-715 (1988).
Apparatus
One embodiment of the instant disclosure relates to a
device or apparatus for cell counting and/or differentiating.
In particular embodiments, the device or apparatus com-
prises a substrate formed from a material, such as silicon,
glass, plastic, metal, or other material. One particular
embodiment of the instant disclosure was fabricated using
soft lithography. Quake, Science 290, 1536-40 (2000). Other
photolithographic or etching techniques could also be used,
according to specific embodiments.
One embodiment of the device was microfabricated using
two parts of PDMS (polydimethylsiloxane) (Sylgard 184.
Dow Corning, MI, USA) mixed vigorously in 10:1 ratio.
After degassing in vacuum for about 30 minutes, the mixture
was poured onto DRIE-eteched silicon mold, that had been
pretreated with HMDS (hexamethyldisilazane) for easy
separation after baking. The molds were baked at 80° C. for
30 minutes. The hardened PDMS was separated from the
silicon mold, and PDMS sheet was cut into pieces and
fluidic access holes were punctured on each piece with a
Luer stub adapter (Becton Dickinson, NJ, USA). Each
PDMS piece was carefully placed on a cleaned glass slide
and baked overnight at 80° C. In some cases, oxygen plasma
treatment (300 m Torr, 25 W, 30 s) was used for PDMS and
glass slides in order to improve adhesion between them,
particularly with devices that were intended to be reused.
Bhattacharya et al., J. Microelectromechan. Syst. 14, 590-97
(2005).
In one particular embodiment, the channel structure was
molded on a 1 cmxI cm PDMS block, with the thickness of
the PDMS block at less than 3 mm. in one particular
embodiment the channel depth was 16 µm in order to
accommodate large leukocyte sizes.
One exemplary embodiment of the device is shown in
FIG. 2. For this particular embodiment, a first fluid flow inlet
200 allows for deposition of, for example sheath flow fluid,
and is in fluid communication with a bifurcated channel with
a first channel arm 260 and a second channel arm 270 that
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both converge at a junction of a reservoir 290 and the
detection zone 240. In this particular embodiment, the
apparatus further comprises a second fluid flow inlet 210
that allows for deposition of, for example, a sample fluid,
such as blood, that is in fluid communication with a filter 5
array structure 230, by way of a branched sample flow zone
channel 220 and a fluid flow outlet 250. In this particular
exemplary embodiment, 2-D hydrodynamic focusing was
adopted to control the particle position of the cell sample in
the detection zone 240. According to the embodiment shown io
in FIG. 2, the ratio of cross-sectional area of sheath flow to
core sample flow was 10:1, and the channel width of the
detection zone 240 was 50 µm, with the width of the focused
sample flow preferably 5µm or less. In particular embodi-
ments, the channels comprise a physical feature, such as a 15
depression or a protrusion.
One other exemplary embodiment of the device is shown
in FIG. 13A. For this particular embodiment, the fluid flow
inlet 1340 allows for deposition of a sample fluid, such as a
biological sample, or other fluid sample containing a target. 20
In one particular embodiment, the biological sample
includes a cell sample, such as blood. In this exemplary
embodiment, the fluid inlet is in fluid communication with
a first channel 1330 which contains a restrictive access 1320
that is juxtaposed to a second channel 1310 which comprises 25
the detection zone which is also in fluid communication with
the fluid flow outlet 1300. In certain embodiments, the
height of the first and/or second channels is approximately
5 µm, approximately 8µm, approximately 10 µm, approxi-
mately 12 µm, approximately 15 µm, approximately 20 µm, 30
approximately 25 µm, approximately 30 µm, approximately
35 µm, approximately 40 µm, or any value therebetween. In
certain embodiments, the width of the second channel is
approximately 5µm, 10 µm, approximately 15 µm, approxi-
mately 20 µm, approximately 25 µm, approximately 30 µm, 35
approximately 35 µm, approximately 40 µm, approximately
45 µm, approximately 50 µm, or any value therebetween. In
the exemplary embodiment shown in FIG. 13A, the second
channel width was approximately 20 µm in size.
One other exemplary embodiment of the device is shown 40
in FIG. 13B. For this particular embodiment, the fluid flow
inlet 1440 allows for deposition of a sample fluid, such as a
biological sample, or other fluid sample containing a target.
In one particular embodiment, the biological sample
includes a cell sample, such as blood. In this exemplary 45
embodiment, the fluid inlet is in fluid communication with
a first channel 1430 which contains a restrictive access 1420
that is juxtaposed to a second channel 1410 which comprises
the detection zone which is also in fluid communication with
the fluid flow outlet 1400. In certain embodiments, the 50
height of the first and/or second channels is approximately
5 µm, approximately 8µm, approximately 10 µm, approxi-
mately 12 µm, approximately 15 µm, approximately 20 µm,
approximately 25 µm, approximately 30 µm, approximately
35 µm, approximately 40 µm, or any value therebetween. In 55
certain embodiments, the width of the second channel is
approximately 5µm, 10 µm, approximately 15 µm, approxi-
mately 20 µm, approximately 25 µm, approximately 30 µm,
approximately 35 µm, approximately 40 µm, approximately
45 µm, approximately 50 µm, or any value therebetween. In 60
the exemplary embodiment shown in FIG. 13B, the second
channel width was approximately 30 µm in size.
Certain embodiments of the device use a focused laser
source for illumination, since cell focusing in the detection
zone 240 is highly desirable. However, other embodiments 65
included in the present disclosure use a more uniform
diffused light source and a slit aperture. Such embodiments
8
utilize straight channel geometry without cell focusing. In
one embodiment, the channel length of the detection zone
240 is 1000 µm. Afilter structure 230 upstream of the sample
flow zone 220 may also be included in certain embodiments,
which filtered out contaminants, including erythryocyte rou-
leaux, and other large particle aggregates to prevent clog-
ging in the detection zone 240. In certain embodiments, the
size of the rectangular pillar structure components of the
filter structure 230 was 200 µmx40 µm. The spacing
between the pillars in each of the three rows was 40 µm, 30
µm, and 20 µm respectively, which allows for even the
largest leukocytes to pass through the filter region 230.
System
The optical system was set up on an optical bench as
shown in FIG. 3 (transmitted laser-induced fluorescent
detection system or LIF). In one particular embodiment, the
system setup comprises an excitation or laser source 300, a
lens assembly 340, the microfluidic apparatus 350, an
optional additional lens assembly 360, a filter assembly 320,
330, and an image capture device 390, 395. In certain
embodiments, one or more emission filters comprise the
filter assemblies 320, 330. In certain embodiments, the
image capture device 395 comprises a charge coupled
device (CCD) camera, a complementary metal-oxide-semi-
conductor (CMOS) device, or a photomultiplier tube (PMT)
device. In particular embodiments, the image capture device
395 may be coupled to communicate with a display unit or
computing device 396, such as a personal computer. One of
skill in the art would recognize that multiple and various
computer software programs are available that allow for
integration, compilation, analysis, reconfiguration, and other
manipulation of data received from the system, particularly
by way of the computing device 396.
In one particular exemplary embodiment, an argon laser
(National Laser NLC210BL, 488 mu, and 15-30 mW adjust-
able, Salt Lake City, Utah, USA) is used as the excitation
source. An aperture 310 of 50 µm diameter is put in front of
the laser output to facilitate the alignment process and lower
the illumination intensity. In certain embodiments, an
optional laser-line bandpass filter (bandwidth equal to about
1.9 nm with a central wavelength of 488 mu) is used to
further purify the laser source. In certain other embodiments,
an optional neutral density filter (NDF) is used to attenuate
laser excitation. Alternatively, the pinhole and NDF are
replaced by two linear glass polarizers (Edmond Optics
TECH SPEC, Barrington, N.7., USA) so that the illumina-
tion level on the device can be easily adjusted.
In one particular embodiment, a long-working-distance
microscope objective (USMCO M Plan Apo, 10x, 0.28 NA,
Dayton, Nev., USA) is used as a condenser lens 340.
Another long-working-distance microscope objective
(Bausch & Lomb, 50x, 0.45 NA, Rochester, N.Y., USA) is
used as an objective lens 360. In the same embodiment, three
emission filters 320 are used in one particular test: 488 mn
long pass filter (Chroma H1500 LP, transition width<4.9 mu,
edge steepness=2.5 mu, Rockingham, Vt., USA), a green
bandpass filter with central wavelength 525 mn and a
bandwidth 50 mn (Chroma D525_50 m), and a red bandpass
filter with central wavelength 650 mn and bandwidth 50 mn
(Chroma D650_50 m). A broadband non-polarizing hybrid
cube beamsplitter 370 (Newport 05BC17MB.1, 400-700
mu, R/T=45%/45%, Irvine, Calif., USA) is used to direct
light to the photodiode detector 380 and CCD camera
simultaneously.
The signal is electrically amplified and detected either
with a silicon photodiode receiver module 390 (Electro-
Optical Systems, UVS-025-H, Phoenixville, Pa., USA) or a
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photon multiplier tube (PMT, Hamamatsu H5784-20,
Japan). The voltage signal is sent to a deep memory oscil-
loscope (HP 54645A, Palo Alto, Calif., USA). When the
buffer in the oscilloscope is full, the data can be loaded to a
computer and analyzed with a Matlab peak-detection pro- 5
gram. Video may be taken with an analog CCD camera
(Hitachi KP-D20B, Japan) at 30 frames per second and then
converted to digital format and stored in a computer 396.
Other imaging capture devices 395, such as CMOS, PMT, or
still other devices may also be used with particular embodi- io
ments described herein. In certain exemplary test runs, the
system set up utilizing a photodiode detector and PMT are
more sensitive than the CCD camera and have a faster time
response. During one exemplary test run, the optical system
was first roughly aligned on a dummy device with the aid of 15
images from CCD camera. A 10 µm diameter illumination
spot on the detection zone is easily achieved with proper
alignment.
As shown in FIG. 12A and FIG. 12B, the instant apparatus
may be incorporated into a hand-held unit comprising a laser 20
source (such as a laser emitting diode or LED 120), at least
one lens 190, at least one filter assembly with optional
beamsplitter 195, a microfluidic apparatus as described
herein on a microchip or other substrate 185, an input/output
port 130, at least one image capture device 100, 110, which 25
may be a photomultiplier tube. In certain embodiments, the
hand-held unit may be assembled and enclosed by an outer
casing or casings 150, 180, and rivets or bolts 140, 160.
Cell Detection
One aspect of the instant disclosure relates to methods of 30
counting and/or differentiating cells, particularly leukocytes,
from undiluted cell samples, such as human or other animal
blood, by utilizing microfabricated devices. In one exem-
plary embodiment, cell detection was conducted utilizing
Acridine orange and fresh whole human blood. 35
In one exemplary embodiment, fresh human blood was
obtained from healthy donors and used within 3 days of
collection. EDTA was added to the blood samples in order
to prevent coagulation. For Acridine orange staining, the
stock solution was added to obtain a final dye concentration 40
of 10 µg/mL in Ficoll-Paque Plus. Ficoll-Paque Plus was
also used as the sheath flow solution. Fluorescent polysty-
rene beads (5 µm green fluorescent beads) were purchased
from Duke Scientific Corporations, Fremont, Calif., USA.
Cell nucleus stain Acridine orange was obtained from 45
Molecular Probes, Eugene, Oreg., USA, and dissolved in
water to achieve a 10 mg/mL stock solution. Blood diluent
Ficoll-Paque Plus was purchased from Amersham Biosci-
ences, Sweden. Phosphate buffered saline (10xPBS) was
obtained from Ambion (9625), Austin, Tex., USA. 50
Staining results were observed under a fluorescent micro-
scope (Nikon E800, Japan) with a triple band fitter block
DAPI-FITC-TRITC, which has excitation filter wavelengths
of 385-400 mu, 475-490 mu, and 545-565 mu, and emission
filter wavelengths of 450-465 nm, 505-535 nm and 580-620 55
mu. Images were taken with a cooled CCD camera (RT-KE
color 3-shot, Diagnostic Instruments, Sterling Heights,
Mich., USA). Rough count of leukocytes was made with a
hemactyometer (Hausser Scientific, Horsham, Pa., USA).
When necessary, blood or fluorescent beads were diluted 60
with Ficoll-Paque Plus (specific gravity 1.077 g/mL) to
match the specific gravity of the solvent to leukocytes. All
fluids were pumped into the devices using syringe pumps
(Harvard Apparatus Pico Plus, Holliston, Mass., USA).
In this particular embodiment, an analog CCD camera 65
was used for video recording at a matched camera frame rate
of 3 nL/min sample flow rate and 30 nL/min sheath flow
10
rate. For photodiode detection, a 0.1 µL/minute sample flow
rate and a 1µL/minute sheath flow rate were used. A 1
µL/minute sample flow and a 10µL/minute sheath flow were
used with the photon multiplier tube instrument.
In order to achieve a high signal-to-noise ratio, the
maximal concentration for cell staining was established
using routine methods in the art. Adams and Kamentsky,
Acta Cytol. 15; 289 (1971). As shown in FIG. 4, whole blood
samples were analyzed with different Acridine orange con-
centrations. The optimal concentration for leukocyte stain-
ing was determined to be approximately in the range of 1
µg/mL. In the particular exemplary embodiment utilized in
FIG. 4, the distance between the coverslip and the grid
surface was approximately 100 µm. As can be seen in FIG.
4A, an abundance of erythrocytes were present under the
field of view, yet these cells did not interfere with the
fluorescent signal from the leukocytes, as shown in FIG.
4B-F.
As can be seen in FIG. 5, the exemplary embodiment
utilized in cell detection did not experience any significant
photobleaching. The signal was fitted as a first-order expo-
nential decay with time constant of 6.4+/-0.7 seconds. Two
more tests confirmed that the photobleaching time constant
for one particular embodiment was between 1 second and 10
seconds. The photobleaching time constant for one particu-
lar embodiment was characterized by filling the device with
Acridine orange-stained whole blood. The channel was
scanned by the laser spot and the illumination was set to be
the same as that used in testing. The entire process was
recorded with a CCD camera. Whenever a fluorescing
leukocyte was observed with fluorescent emission clearly
distinct from the background, we stopped moving the laser
spot and waited until the leukocyte was photobleached to
background level. The images were extracted from the
video, converted to 8-bit gray scale images, and analyzed
with a Matlab program. The data was fitted to a single
time-constant exponential decay.
Additionally, green fluorescent beads were tested at a
concentration of about 2x103/µL, as observed by CCD
camera, and shown in FIG. 6. Sample flow rate was set at
about 3 nL/min, and sheath flow was about 30 nL/min. In
one exemplary test run, a hydrodynamic focused laser beam,
as shown in FIG. 6A, created an enlarged light circle as
shown in FIG. 6B. Only a single bead normally appeared in
each image. With diffused laser illumination, as shown in
FIG. 6C, the trace of the bead could be identified, as shown
in FIG. 6D. Hydrodynamic focusing limits the cross-sec-
tional area of the detection zone without shrinking the
channel diameter, thus the signal-to-noise ratio may be
improved without increasing the risk of clogging the chan-
nel. Also, the reduction of the cross-section of the core flow
reduces the coincidence effect. Finally, enclosing the core
sample flow with sheath flow minimizes fluorescent dye
absorption in the device walls, thus reducing background
noise. As indicated in FIG. 7, bead signals from the photo-
diode detector could easily be identified.
As shown in FIG. 8, using both red and green emission
filters, images extracted from video taken by the CCD
camera show the signal identified from a leukocyte stained
with Acridine orange, as well as the signal obtained from the
fluorescent control bead. For photodiode detection, the
expected leukocyte detection rate would average about 4-11
cells per second for a normal individual.
In one exemplary embodiment, a time trace over 50
seconds of an undiluted blood sample stained with Acridine
orange using a green emission filter, and a throughput of up
to about 1000 leukocytes per second was attained. Maxima
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signal intensity (peak height as in FIG. 9) from the green
fluorescent channel with 525 mu emission filter was studied
by plotting its histogram, as shown in FIG. 10. As expected,
the lower-intensity portion is likely contributed mainly by
lymphocytes, while the higher-intensity portion is likely
mainly from monocytes, with the center-region is likely
mostly from granulocytes. Steinkam et al., Acta Cytol. 17;
113-117 (1973).
In one exemplary embodiment, a time trace over 50
seconds of an undiluted blood sample stained with Acridine
orange using a red fluorescent channel with 650 mu emis-
sion filter was conducted. As shown in FIG. 11, two peaks
were identified, the lower intensity is dominated by lym-
phocytes and the higher-intensity peak is largely monocytes
and granulocytes. The time between the start of staining the
cells to photodiode recording was typically greater than 15
minutes.
In both exemplary studies, the maximal throughput was
about 1000 leukocytes per second utilizing one embodiment
of the PMT detector. By using undiluted blood, minimal
sample volume was maintained, which increases the
throughput. Since sample throughput is proportional to
volume flow rate, but is limited by the maximal pumping
rate and response time of the sensing system, a 3 nL/minute
core flow rate was used with the CCD camera detection.
Under this flow rate, a typical leukocyte traveled through the
detection zone in approximately 30 milliseconds, which
roughly equals the CCD frame acquisition time.
Flow rates for varying embodiments may be suitable for
a range from approximately 1 nL/minute, approximately 2
nL/minute, approximately 3 nL/minute, approximately 4
nL/minute, approximately 5 nL/minute, approximately 6
nL/minute, approximately 7 nL/minute, approximately 8
nL/minute, approximately 9 nL/minute, approximately 10
nL/minute, approximately 20 nL/minute, approximately 30
nL/minute, approximately 40 nL/minute, approximately 50
nL/minute, approximately 60 nL/minute, approximately 70
nL/minute, approximately 80 nL/minute, approximately 90
nL/minute, approximately 100 nL/minute, approximately
110 nL/minute, approximately 120 nL/minute, approxi-
mately 130 nL/minute, approximately 140 nL/minute,
approximately 150 nL/minute, or any value therebetween
for photodiode detection. Likewise, for PMT detection, flow
rates for varying embodiments may be suitable for a range
from approximately 200 nL/minute, approximately 300
nL/minute, approximately 400 nL/minute, approximately
500 nL/minute, approximately 600 nL/minute, approxi-
mately 700 nL/minute, approximately 800 nL/minute,
approximately 900 nL/minute, approximately 1µL/minute,
approximately 2µL/minute, approximately 3µL/minute,
approximately 4µL/minute, approximately 5µL/minute, or
any value therebetween.
In one exemplary embodiment, the time response of the
photodiode receiver module under low sensitivity setting
was 0.16 milliseconds, and 0.6 milliseconds under high
sensitivity, while the time response of the PMT detector in
one exemplary run was about 16 microseconds.
Furthermore, by decreasing the cross-sectional area, the
linear flow velocity of the core flow is increased, which
requires faster sensing, and reduces the coincidence effect by
increasing the average distance between cells in the detec-
tion zone.
Thus, by utilizing particular embodiments disclosed
herein relating to a microfluidic device, leukocyte sensing,
counting, and sorting can be achieved one-by-one in a micro
flow cytometer system. Furthermore, dense cell suspensions,
such as whole, undiluted blood may be utilized in certain
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embodiments described herein, which provides for reduced
sample and waste volume, reduced processing time, and
completely eliminates on-chip mixing and buffer storage. In
particular aspects, leukocytes can be sensed one-by-one in a
5 micro flow cytometer system.
As described herein, certain embodiments of the device
can be implemented in various sizes and conformations,
including but not limited to a bench-top device, a handheld
device (such as is shown in FIG. 12), an implantable device,
io a nanotechnology device, or other size or conformation. In
the smaller exemplary conformations, high-illumination
LED is used for excitation and a minipump is used to
manipulate the sample in suction mode, while fluorescent
signals from green and red channels can be detected simul-
15 taneously.
INCORPORATION BY REFERENCE
All of the above U.S. patents, U.S. patent application
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25 The invention claimed is:
1. A system for analyzing cells, the system comprising:
a sample comprising fluorescently labeled cells and fluo-
rescently labeled control beads, wherein the fluores-
cently labeled cells are labeled with a fluorophore
30 different than a fluorophore label of the control beads;
a first microfluidic channel comprising an inlet configured
to receive the sample and an outlet, wherein the first
microfluidic channel (1) comprises a cross sectional
area that decreases towards the outlet of the first
35 microfluidic channel, and (2) increases a linear velocity
of a core flow of the sample as the sample flows from
the inlet to the outlet of the first microfluidic channel;
a second microfluidic channel comprising an inlet coupled
to the outlet of the first microfluidic channel, an outlet
40 and a detection zone, wherein the sample is configured
to flow from the inlet through the detection zone and
towards the outlet of the second microfluidic channel;
an excitation source configured to excite the fluorophores
of the fluorescently labeled cells and of the fluores-
45 cently labeled control beads as they pass through the
detection zone;
a sensor configured to detect fluorescence of the fluores-
cently labeled cells and the fluorescently labeled con-
trol beads as they pass through the detection zone,
50 wherein system is capable of performing the detection
on individual fluorescently labeled cells; and
one or more processors configured to process the detected
fluorescence of the fluorescently labeled cells and the
fluorescently labeled control beads.
55 2. The system of claim 1, wherein the second microfluidic
channel has fixed dimensions.
3. The system of claim 2, wherein the fixed dimensions
are of approximately 40 microns by approximately 50
microns.
60 4. The system of claim 1, wherein a length of the detection
zone is equal to or about 1000 µm.
5. The system of claim 1, wherein the sample comprises
undiluted blood sample.
6. The system of claim 5, wherein the undiluted blood
65 sample is stained with dye.
7. The system of claim 6, wherein the dye is acridine
orange.
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8. The system of claim 1, wherein the sample comprises
treated blood sample.
9. The system of claim 1, wherein the excitation source
comprises a laser or LED.
10. The system of claim 9, wherein the laser is an argon 5
laser.
11. The system of claim 1, wherein the excitation source
is configured to provide a focused light source for illumi-
nation.
12. The system of claim 1, wherein the fluorescently io
labeled beads are polymeric or polystyrene beads.
13. The system of claim 1, wherein the system is capable
of detecting fluorescence of the fluorescently labeled cells at
a rate of up to about 1000 cells per second.
14. The system of claim 1, wherein the first channel is 15
obstacle-free.
15. The system of claim 1, wherein the second channel is
obstacle-free.
16. The system of claim 1, wherein the fluorescently
labeled cells are leukocytes. 20
17. The system of claim 1, wherein the sensor comprises
a CCD sensor array, photodiode, or photomultiplier tube.
18. The system of claim 1, wherein the one or more
processors are further configured to output data regarding
the detected fluorescence of the fluorescently labeled cells. 25
19. The system of claim 18, further comprising a display
unit for displaying the data.
20. The system of claim 1, wherein the one or more
processors are further configured to count a number of the
fluorescently labeled cells. 30
